Advancements in Gastroenterology: A Weekly Review
Gastroenterologia
The New Map of Crohn’s Disease: Beyond Inflammation
Crohn’s disease treatment is undergoing a radical transformation.
This week, Advancements in Gastroenterology explores the emerging science reshaping how we understand and manage inflammatory bowel disease — from global trends in pediatric IBD and the promise of GLP-1 receptor agonists to the precision power of biologics like risankizumab and novel insights into the tuft cell–IL-25 axis.
Join us as we uncover how the gut-brain connection, microbiome modulation, and personalized medicine are rewriting the future of Crohn’s disease care.
Bibliography
- Al-Beltagi M. et al. Inflammatory Bowel Disease in Paediatrics: Navigating Old Challenges and Emerging Frontiers. World J Gastroenterol. 2025;31(35):111934. doi:10.3748/wjg.v31.i35.111934
- Colwill M. et al. GLP-1 Receptor Agonists in Inflammatory Bowel Disease: Mechanisms, Clinical Implications, and Therapeutic Potential. J Crohns Colitis. 2025;19(9):jjaf167. doi:10.1093/ecco-jcc/jjaf167
- Giri S. et al. Fatigue in Inflammatory Bowel Disease: Prevalence, Risk Factors, and Management. World J Gastrointest Pathophysiol. 2025;16(3):107573. doi:10.4291/wjgp.v16.i3.107573
- Udine M. et al. Isolated Gastric Crohn’s Disease: A Case Report. ACG Case Rep J. 2025;12(9):e01790. doi:10.14309/crj.0000000000001790
- Sigall Boneh R. et al. Modified Crohn’s Disease Exclusion Diet Maintains Remission in Pediatric Crohn’s Disease: Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2025;23(11):2001–2011. doi:10.1016/j.cgh.2024.12.006
- Pagano M. et al. Endoanal Ultrasound in Perianal Crohn’s Disease. J Clin Med. 2025;14(19):6867. doi:10.3390/jcm14196867
- Panaccione R. et al. Extended Risankizumab Treatment in Crohn’s Disease Patients Without Initial Response to Induction. Clin Gastroenterol Hepatol. 2025;23(11):2012–2022.e6. doi:10.1016/j.cgh.2024.12.023
- Yanofsky R. et al. Association Between Inflammatory Bowel Disease and Eosinophilic Esophagitis: A Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2025;31(10):2895–2906. doi:10.1093/ibd/izaf095
- Sakakibara R. et al. Adjustment of Surveillance Intervals for Ulcerative Colitis-Associated Neoplasia Based on Disease Duration. Dig Endosc. 2025;37(10):1068–1077. doi:10.1111/den.15073
- Tao Z. et al. The Tuft Cell–Interleukin-25 Axis in the Pathogenesis of Inflammatory Bowel Disease. Front Immunol. 2025;16:1629060. doi:10.3389/fimmu.2025.1629060
